<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00659451</url>
  </required_header>
  <id_info>
    <org_study_id>UNIPV002DIM2008</org_study_id>
    <nct_id>NCT00659451</nct_id>
  </id_info>
  <brief_title>Effects Of Losartan On Myocardial Structure In Diabetic Hypertensive Patients With Left Ventricular</brief_title>
  <official_title>Effects Of Losartan On Myocardial Structure And Function And On Epicardial Fat Deposition In Diabetic Hypertensive Patients With Left Ventricular: Qualitative And Quantitative Alteration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pavia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Pavia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The anthypertensive treatment with Losartan may have benefits beyond blood pressure reduction
      on myocardial structure and function in hypertensive diabetic patients. We will evaluate the
      effect of losartan treatment on structural characteristics of myocardium in hypertensive
      diabetic patients:

        1. left ventricular mass, intraventricular septal thickness, fractional shortening.

        2. myocardial qualitative alteration and heterogeneity of myocardial tissue that describes
           myocardial texture and echodensity, related to collagen deposition; myocardial
           qualitative alteration will be evaluate by ultrasonic myocardial integrated backscatter
           signals (IBS) both as peak end diastolic signal intensity and as cardiac cyclic
           variation

        3. alteration of diastolic function as studied by Doppler flow velocities across the mitral
           valve (Pulse Wave Doppler) and pulse wave Tissue Doppler Imaging parameters

        4. aortic strain and distensibility (that is in relation with LVH)

        5. epicardial adipose tissue measurement (this parameter is related to the visceral fat and
           may be an easy method to indicate patients with high cardiovascular risk).
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2008</start_date>
  <completion_date type="Anticipated">April 2009</completion_date>
  <primary_completion_date type="Actual">April 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Left ventricular mass, intraventricular septal thickness, fractional shortening; myocardial qualitative and diastolic function alteration; aortic strain and distensibility.</measure>
    <time_frame>Between 08.00 and 10.00 at baseline, and after 3, 6, and 12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Heterogeneity of myocardial tissue; epicardial adipose tissue measurement</measure>
    <time_frame>Between 08.00 and 10.00 at baseline, and after 3, 6, and 12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Essential Hypertension</condition>
  <condition>Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Losartan</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Amlodipine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Losartan</intervention_name>
    <description>tablets; 50, 100 mg; od; 12 months</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amlodipine</intervention_name>
    <description>tablets; 5, 10 mg; od; 12 months</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Gender: 50% Male and 50 % female

          -  Age: 40-80 years

          -  Race: caucasian

          -  Well controlled type II Diabetes : fasting glicemia &lt; 126 mg/dl in two different
             determinantion or any non fasting glicemia &gt; 200 mg/dl; HbA1c &lt; 7%

          -  Mild to moderate hypertension (BP&gt;130/80mmHg; &lt;160/100mmHg)

          -  Left ventricular hypertrophy (LVMI &gt; 131/110 g/m2 in males/females respectively)

        Exclusion Criteria:

          -  other anthypertensive treatment after wash out period of 2 weeks

          -  abnormal heart rest function (EF &lt; 55%).

          -  valvular heart disease

          -  congenital heart disease

          -  heart failure or prior myocardial infarction

          -  renal disease

          -  liver disease

          -  connective tissue disease

          -  pregnancy or lactation

          -  sensitivity to the study drugs

          -  contraindication from an approved label
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Roberto Fogari</last_name>
    <phone>+39 0382 526217</phone>
  </overall_contact>
  <location>
    <facility>
      <name>University of Pavia</name>
      <address>
        <city>Pavia</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paola Preti, MD</last_name>
      <phone>+39 0382 526217</phone>
    </contact>
    <investigator>
      <last_name>Paola Preti</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>April 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 14, 2008</study_first_submitted>
  <study_first_submitted_qc>April 14, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 16, 2008</study_first_posted>
  <last_update_submitted>April 14, 2008</last_update_submitted>
  <last_update_submitted_qc>April 14, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 16, 2008</last_update_posted>
  <responsible_party>
    <name_title>Paola Preti/MD</name_title>
    <organization>University of Pavia</organization>
  </responsible_party>
  <keyword>Hypertension</keyword>
  <keyword>Diabetes mellitus</keyword>
  <keyword>Heart</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amlodipine</mesh_term>
    <mesh_term>Losartan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

